Frankfurt
12.08.24
15:29 Uhr
0,048 Euro
0,000
0,00 %
0,00 %
1-Jahres-Chart (nicht börsennotiert)
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.08. | Biotech Destiny Pharma Tips Into Insolvency in Cash Crisis | 3 | BNN Bloomberg | ||
| 20.08. | JP Jenkins Ltd: Destiny Pharma to Deliver Presentation at the European Society of Clinical Microbiology and Infectious Disease conference on XF-73 Nasal Gel and the Use of Post-Operative Antibiotics in Cardio-vascula | 320 | EQS Group (EN) | JP Jenkins Ltd
Destiny Pharma to Deliver Presentation at the European Society of Clinical Microbiology and Infectious Disease conference on XF-73 Nasal Gel and the Use of Post-Operative... ► Artikel lesen | |
| 14.08. | JP Jenkins Ltd: Destiny Pharma initiates research to explore XF drug potential for CF | 268 | EQS Group (EN) | JP Jenkins Ltd
Destiny Pharma initiates research to explore XF drug potential for CF 14-Aug-2024 / 11:20 GMT/BST
The issuer is solely responsible for the content of this announcement.
... ► Artikel lesen | |
| 13.08. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 13.08.2024 | 439 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 13.08.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 13.08.2024ISIN NameCA44053J4090 HORIZON... ► Artikel lesen | |
| 13.08. | JP Jenkins Ltd: Destiny Pharma plc shares now trading on JP Jenkins | 204 | EQS Group (EN) | JP Jenkins Ltd
Destiny Pharma plc shares now trading on JP Jenkins 13-Aug-2024 / 09:36 GMT/BST
The issuer is solely responsible for the content of this announcement.
13th Aug... ► Artikel lesen | |
| 13.08. | AIM - Cancellation - Destiny Pharma plc | 1 | RNS | ||
| 13.08. | XFRA D89: AUSSETZUNG/SUSPENSION | 159 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILDESTINY PHARMA PLC... ► Artikel lesen | |
| 12.08. | Destiny Pharma PLC - Last Day of Dealings on AIM | - | RNS | ||
| DESTINY PHARMA Aktie jetzt für 0€ handeln | |||||
| 06.08. | FTSE Russell - Destiny Pharma: Constituent Deletion - Changes in FTSE UK Index Series | 2 | RNS | ||
| 05.08. | Small Cap Stocks: Destiny Pharma, Tower Resources, UK Oil & Gas | 2 | The Armchair Trader | ||
| 05.08. | Destiny Pharma reports positive findings from XF-73 study | 1 | Sharecast | ||
| 05.08. | Destiny Pharma PLC - Director/PDMR Shareholding | 1 | RNS | ||
| 05.08. | Destiny Pharma shares fall amid XF-73 fending off MRSA in wounds | 1 | Alliance News | ||
| 05.08. | Destiny Pharma PLC - XF-73 prevents bacterial invasion of bloodstream | 1 | RNS | ||
| 31.07. | Destiny Pharma PLC - Result of GM and Cancellation of Trading on AIM | 1 | RNS | ||
| 22.07. | Small Cap Stocks: Future Metals, Wishbone Gold, Destiny Pharma | 4 | The Armchair Trader | ||
| 22.07. | Destiny Pharma PLC - Treatment of XF-73 Nasal reduces antibiotic use | 1 | RNS | ||
| 15.07. | Small Cap Stocks: Gfinity, Caspian Sunrise, Destiny Pharma | 2 | The Armchair Trader | ||
| 15.07. | London markets weak at midday, Burberry, Destiny Pharma smashed | 4 | Shares | ||
| 15.07. | AIM WINNERS & LOSERS: Destiny Pharma falls on plans to go private | 1 | Alliance News |
Seite:
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CORE ONE LABS | 0,079 | -100,00 % | New Core One 3D Printer From Prusa May Be the Answer to Its Bambu Problem | ||
| SKINBIOTHERAPEUTICS | 0,173 | -2,26 % | SkinBioTherapeutics - Finalisation of commercial agreement with Croda | ||
| ADMA BIOLOGICS | 21,370 | 0,00 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| RECURSION PHARMACEUTICALS | 6,040 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| EVOTEC | 9,685 | -2,22 % | Evotec: Extreme Ausschläge | Größer könnten die Gegensätze wohl kaum sein. Die Aktie von Evotec hat im zurückliegenden Jahren einen massiven Einbruch erfahren. Auf 52-Wochen-Sicht gehört sie zu den schlechtesten Aktien im SDAX.... ► Artikel lesen | |
| QIAGEN | 40,110 | +3,27 % | DAX fehlen die Impulse. Qiagen deutet Gegenbewegung an | ||
| QUANTUM-SI | 1,400 | 0,00 % | Quantum-Si Inc - 8-K, Current Report | ||
| 89BIO | 7,980 | 0,00 % | 89bio, Inc.: 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting 2024 | SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,76 | 0,00 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
| RELAY THERAPEUTICS | 4,660 | 0,00 % | Aktie von Relay Therapeutics erreicht 52-Wochen-Tief bei 5,59 US-Dollar | ||
| STRUCTURE THERAPEUTICS | 32,710 | 0,00 % | Structure Therapeutics reports Q3 results | ||
| SPRINGWORKS THERAPEUTICS | 37,440 | 0,00 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
| 4D MOLECULAR THERAPEUTICS | 8,410 | 0,00 % | Analyst Expectations For 4D Molecular Therapeutics' Future | ||
| DYNE THERAPEUTICS | 30,000 | 0,00 % | Dyne Therapeutics: Leitender Vizepräsident veräußert Aktien im Wert von 77.127 US-Dollar | ||
| CULLINAN THERAPEUTICS | 12,580 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 | Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases Cullinan will share details of global Phase... ► Artikel lesen |
Das Unternehmen DESTINY PHARMA PLC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,048 Euro.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DESTINY PHARMA PLC finden Sie auf Wallstreet Online.
